MOD3 Pharma

What MOD3 Pharma does

MOD3 Pharma is a privately held, clinical-stage biopharmaceutical company founded in 2013 and headquartered in Boonton, New Jersey. The company operates with a small headcount of 1-10 employees, consistent with a micro-cap, pre-commercial biotech operating profile. Its corporate web presence is hosted at enterisbiopharma.com, indicating a likely branding or corporate continuity relationship with Enteris BioPharma, though the specific nature of this linkage (asset transfer, partnership, or simple domain reuse) is not clarified in the available material.

Beyond these foundational facts, the input data does not enumerate MOD3 Pharma's therapeutic focus, indication areas, pipeline assets, underlying technology platform, or development stage for any specific compound. No product candidates, clinical trial registrations, regulatory designations, partnership arrangements, licensing deals, or funding rounds are disclosed. The company's business model — whether internally funded, venture-backed, grant-supported, or partnered — is therefore not characterizable from the provided material, and the absence of revenue, pricing, or customer information is consistent with a pre-commercial clinical-stage posture.

Name

MOD3 Pharma

Website

https://enterisbiopharma.com

Company type

Private

Founded year

2013

Headcount range

1–10 employees

Short description

MOD3 Pharma is a privately held, clinical-stage biopharmaceutical company founded in 2013 and headquartered in Boonton, New Jersey, operating with 1-10 employees and led by CEO Rajiv Khosla.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Clinical-stage biopharmaceuticals
• Drug development
• Pharmaceutical R&D
• Biopharmaceutical pipeline
• Therapeutic candidates

Headquarters

HQ city

Boonton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

MOD3 Pharma is a privately held, clinical-stage biopharmaceutical company developing pharmaceutical therapeutic candidates. The firm operates with 1-10 employees and is headquartered in Boonton, United States, and is associated with the website enterisbiopharma.com. As a clinical-stage entity, its core activity is research and development of drug candidates intended for eventual commercialization or licensing.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• Enteris BioPharma: Enteris BioPharma is a clinical-stage company focused on oral peptide and small-molecule drug delivery. MOD3 Pharma's corporate URL resolves to enterisbiopharma.com, indicating a direct corporate continuity or close relationship with Enteris's proprietary Peptelligence oral-delivery platform.
• Oramed Pharmaceuticals: Oramed is a clinical-stage biopharma developing oral delivery platforms for biologic peptides (notably oral insulin). Comparable to MOD3/Enteris in focus on proprietary oral formulation of peptides and biologics — same core technology bet and target therapeutic model.

Broad incumbents

• Halozyme Therapeutics: Halozyme commercializes a proprietary drug-delivery platform (ENHANZE) used by major pharma partners for subcutaneous delivery. It represents the scaled, platform-licensing archetype that MOD3's oral-delivery asset aspires to reach in a smaller specialty CNS/specialty pharma niche.
• Supernus Pharmaceuticals: Supernus is a specialty CNS biopharma commercializing products for ADHD, epilepsy, and Parkinson's. Relevant as a scaled commercial-stage CNS/specialty pharma against which MOD3's smaller CNS-adjacent pipeline would be benchmarked for partnership value.

Emerging players

• Impel NeuroPharma: Impel developed a CNS-focused intranasal drug delivery platform and pursued commercialization. Comparable to MOD3 as a CNS-adjacent specialty pharma built around a proprietary non-oral delivery technology targeting CNS indications.
• Neurelis: Neurelis is a privately held specialty CNS biopharma focused on rescue therapies for neurological conditions. Comparable to MOD3 as a small, CNS-focused specialty pharma with limited infrastructure and an asset-driven value proposition.
• Diasome Pharmaceuticals: Diasome is a small clinical-stage pharma developing a targeted hepatic drug delivery platform. Comparable to MOD3 as a similarly sized clinical-stage platform company with a delivery-technology value proposition.

Others

• Adare Pharmaceuticals Solutions: Adare is a CDMO/technology company with formulation expertise including oral modified-release and taste-masking. Comparable as an industry participant in the oral drug delivery technology space that MOD3/Enteris also operates in.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/enteris-biopharma-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MOD3 Pharma